With gener­ic com­pe­ti­tion heat­ing up, Vas Narasimhan out­lines No­var­tis' growth plans at R&D day

Thurs­day marks No­var­tis’ an­nu­al R&D day, and with it comes CEO Vas Narasimhan’s at­tempt to spot­light the com­pa­ny’s pipeline strat­e­gy and emerg­ing stars.

The biggest ques­tion en­ter­ing Thurs­day’s pre­sen­ta­tion dealt with how the big bio­phar­ma will make up rev­enues from up­com­ing gener­ic com­pe­ti­tion — No­var­tis says with­in the next five years, gener­ics will eat away rough­ly $9 bil­lion in sales. To off­set this, Narasimhan out­lined a strat­e­gy for 4% growth or high­er un­til 2026, fo­cus­ing on six key med­i­cines he be­lieves will see multi­bil­lion dol­lar prof­its dur­ing this time.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN